Age | Tumor Site | Non carriers (%) | BRCA1 carriers (%) | BRCA2 carriers (%) | p |
---|---|---|---|---|---|
≤ 30 | BC | 7 (77.8) | 1 (11.1) | 1 (11.1) | – |
OC | 0 (0) | 0 (0) | 0 (0) | Â | |
31–40 | BC | 44 (86.3) | 4(7.8) | 3 (5.9) | 0.001 |
OC | 1 (25) | 3 (75) | 0 (0) | Â | |
41–50 | BC | 22 (91.7) | 0 (0) | 2 (8.3) | 0.044 |
OC | 7 (77.8) | 2 (22.2) | 0 (0) | Â | |
≥ 51 | BC | 23 (88.5) | 0 (0) | 3 (11.5) | 0.24 |
OC | 11 (100) | 0 (0) | 0 (0) | Â |
Age | TN | Non carriers (%) | BRCA1 carriers (%) | BRCA2 carriers (%) | p |
---|---|---|---|---|---|
≤ 30 | No | 4 (100) | 0 (0) | 0 (0) | 0.358 |
Yes | 3 (60) | 1 (20) | 1 (20) | Â | |
31–40 | No | 34 (89.5) | 1 (2.6) | 3 (7.9) | 0.041 |
Yes | 10 (76.9) | 3 (23.1) | 0 (0) | Â | |
41–50 | No | 17 (89.5) | 0 (0) | 2 (10.5) | 0.449 |
Yes | 5 (100) | 0(0) | 0 (0) | Â | |
≥ 51 | No | 20(87) | 0 (0) | 3 (13) | 0.506 |
Yes | 3 (100) | 0 (0) | 0 (0) | Â |